VLS Retatrutide 20MG

About VLS Retatrutide 20MG

Retatrutide is an investigational triple hormone receptor agonist (targeting GLP-1, GIP, and glucagon receptors) developed by Eli Lilly for the treatment of obesity and type 2 diabetes.   Current clinical trials are evaluating its efficacy and safety for:  Obesity and overweight with weight-related medical conditions.  Type 2 diabetes management. Metabolic dysfunction-associated steatotic liver disease (MASLD).  Knee osteoarthritis pain and chronic low back pain.  Obstructive sleep apnea (OSA) and cardiovascular/renal outcomes.  It is not yet FDA-approved and remains in Phase 3 clinical trials; consequently, it is not currently available for prescription